Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Processa Pharmaceuticals, Inc. (PCSA)

Processa names Sheila Gujrathi Executive Chair; FDA clears CSU IND for VT-7208

Neutral Impact 3 of 5 leadership Written later

Justin Yorke resigned as chair of Processa's board on October 27, 2026, and the board appointed Dr. Sheila Gujrathi as non-employee Executive Chair on October 28, effective immediately; Yorke remains a board member. The October 29 press release also reported FDA clearance of an IND for a Phase 2 study of VT-7208 in chronic spontaneous urticaria and said cash is expected to fund operations into the second half of 2029.

Key points

  • Justin Yorke resigned as board chair on October 27, 2026 and remains a board member.
  • Dr. Sheila Gujrathi was appointed non-employee Executive Chair on October 28, 2026, effective immediately.
  • The FDA cleared the IND for a Phase 2 CSU study of VT-7208 planned to enroll approximately 120 adults.
  • The company expects its cash resources to support operations into the second half of 2029.

The filing

CompanyProcessa Pharmaceuticals, Inc. (PCSA)
Form8-K, current report
Filed with the SECOct 29, 2026, 8:46 AM ET
Accession number0001140361-26-041116

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.